Merck Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS

DARMSTADT, Germany — (BUSINESS WIRE) — Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced updated long-term efficacy and safety da…